Titan IIIB

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

Retrieved on: 
Thursday, November 30, 2023
Pharmaceutical, Health, Clinical Trials, GAIS, Galderma, Patient, Titan IIIB, LCL, Pharmaceutical industry, Botulinum toxin

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).

Key Points: 
  • Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).
  • RelabotulinumtoxinA was well tolerated; the majority of patients did not experience any adverse events and there were no related serious adverse events reported.1
    43QM2107 is a phase IIIb, open-label, single-center study to assess aesthetic improvement of RelabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines.
  • By day two, 100% of patients noted improvement for crow’s feet and 96% noted improvement for frown lines.
  • For frown line severity, 32% of patients on day one and 92% of patients on day four received a score of zero or one.

ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

Retrieved on: 
Wednesday, October 18, 2023
AIDS, Health, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, EACS, MPH, III, Biomarker, Rilpivirine, LA, HIV, Safety, Conference, Research, RWE, Shionogi, Titan IIIB, Pfizer, Lamivudine, Medicine, Abstract, HTE, GSK, XVII International AIDS Conference, 2008, ViiV Healthcare, Viral load, SOLAR, Estonia, Pharmaceutical industry, Vaccine, Fostemsavir, European, Dolutegravir/lamivudine

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.

Key Points: 
  • ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.
  • Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “Living well with HIV looks different for every individual, and we believe our upcoming presentations at EACS 2023 reflect our commitment and leadership to address the evolving needs of the HIV community.
  • Our latest data from our diverse portfolio and innovative pipeline explore real-world evidence that further evaluate the effectiveness, safety, and tolerability of 2-drug and long-acting regimens; new findings for broadly neutralizing antibodies; and long-term follow-up in heavily treatment-experienced individuals.
  • Here is a list of ViiV Healthcare-sponsored or supported studies being presented at EACS 2023:

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia

Retrieved on: 
Tuesday, September 19, 2023
Science, Research, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, BAT, Civil service commission, Polycythemia vera, European Hematology Association, Hydroxycarbamide, Medical school, Multimedia, Ropeginterferon alfa-2b, H, Patient, Titan IIIB, AOP, Annual general meeting, Medical University of Vienna, Paper, ATC, Polycythemia, Leukemia, European Commission, Safety, Disease, Pharmaceutical industry, PV

AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.

Key Points: 
  • AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.
  • The full publication expands on results presented at the Annual Meeting of the European Hematology Association.
  • Results of long-term treatment in the CONTINUATION-PV study provide further evidence of the disease modifying capacity of ropeginterferon alfa-2b in PV.
  • Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Almirall’s First Quarter 2023 Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Pharmaceutical, Health, The New England Journal of Medicine, Medical journal, Safety, Atopic dermatitis, JAMA Dermatology, BJD, Acquisition, Patient, MM, Ciclosporin, Ageing, Disease, Tildrakizumab, Science, American Academy of Dermatology, Face, Pharmacokinetics, Scalp, Advantage, EMA, Titan IIIB, BMJ, Growth, III, Psoriasis, Autoimmune disease, Accounting, Traction, Administration, AAD, Adolescence, American Academy, TRX, Almirall, Trial of the century, NEJM, Advocate, EBITDA, AD, Fine chemical, Medical imaging, Mobile phone, Pharmaceutical industry, Vaccine, EU, Dermatology

We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.

Key Points: 
  • We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.
  • We remain focused on preparing the business for the expected approval of lebrikizumab in late 2023, a product with the potential to transform our company.
  • Almirall is confident that its European business will continue to flourish throughout 2023 with the contribution of new countries where Ilumetri® has been recently launched.
  • In the first quarter of 2023, Almirall announced several positive clinical updates on lebrikizumab.

AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Titan IIIB, BAT, AOP, Union, Royal commission, MPN, Patient, EMA, Research, Critical care, Phlebotomy, PV, Hydroxycarbamide, Drug development, Health, European Commission, Multimedia, Safety, ELN, ATC, ASH, Polycythemia, Renewable energy, Pharmaceutical industry, Bookkeeping, Ropeginterferon alfa-2b

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.

Key Points: 
  • AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.
  • ASH 2022 ) and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health ( Reference Barbui et al.
  • ASH 2022 ) presented at ASH 2022 Annual Meeting, New Orleans, USA.
  • With this development program AOP Health obtained the first marketing authorization ever of BESREMi for the treatment of Polycythaemia Vera by the European Commission (2019), followed by Switzerland, Liechtenstein and Israel.

AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting

Retrieved on: 
Monday, June 20, 2022
Health, Stem Cells, Pharmaceutical, Clinical Trials, Oncology, AOP, EHA, Hematocrit, Hydroxycarbamide, US, Thrombosis, Medical school, Survival, Bone marrow, Disease, Titan IIIB, Quality of life, Health, Death, Ruxolitinib, Group, PV, Solution, Embolism, Interferon, Phlebotomy, BAT, Commonwealth, JAK2, Chronic myelogenous leukemia, European Commission, Product, Royal commission, Commonwealth of Independent States, Critical care, HIV disease progression rates, Leukemia, CIS, Patient, Annual general meeting, Risk, Myeloproliferative neoplasm, Safety, European Hematology Association, Medical University of Vienna, Cancer, Research, CML, ATC, Life, EMA, Goal, Renewable energy, Pharmaceutical industry, Medical device, Ropeginterferon alfa-2b

AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .

Key Points: 
  • AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .
  • The results of CONTI-PV after 7.5 years of treatment provide further evidence of the value of BESREMi for patients suffering from PV.
  • 1 Ropeginterferon alpha-2b achieves patient-specific treatment goals in Polycythaemia Vera: final results from the PROUD-PV/CONTINUATION-PV studies.
  • The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (AOP Health).

Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients

Retrieved on: 
Monday, October 18, 2021
Clinical trial, Clinical Cancer Research, PD-1, Feinberg School of Medicine, Companion diagnostic, FDA, Disease, Survival, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Nivolumab, NK, Private Securities Litigation Reform Act, Colon, Degenerative disease, Ministry of Education (Malaysia), Large-cell lung carcinoma, Paul Ehrlich Institute, Cancer, Doctor of Philosophy, Gesellschaft mit beschränkter Haftung, WHO, PFS, Patient, Food, Titan IIIB, NSCLC, Company, MD, SOC, IND, Therapy, New, CAR, Progression-free survival, US, Neoplasm, III, Thorax, Cell, Associate professor, JD, Leukapheresis, Membrane protein, Lung cancer, Standard of care, Safety, Cohort study, Vaccine, Pharmaceutical industry

We are delighted with the outcome of the Pre-IND meeting with the US FDA which was supported by clinical data from a prior Phase II Clinical Trial involving patients with advanced (stage IIIb) NSCLC in Germany.

Key Points: 
  • We are delighted with the outcome of the Pre-IND meeting with the US FDA which was supported by clinical data from a prior Phase II Clinical Trial involving patients with advanced (stage IIIb) NSCLC in Germany.
  • In the control group of seven (7) patients who received SOC RCT alone, only two (2) patients experienced a clinical benefit.
  • When NSCLC is diagnosed as stage III or stage IV, it is considered advanced; and, 40% of NSCLC patients present at an advanced stage.
  • Targeted natural killer cell based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy a randomized phase II clinical study.